Search Results

A real-world pharmacovigilance study using disproportionality analysis of United States Food and Drug Administration Adverse Event Reporting System events for vinca alkaloids: comparing vinorelbine and Vincristine.

• Authors : Zhong C; Department of Respiratory and Clinical Care Medicine, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.; Zheng Q

Subjects: Vinorelbine*/Vinorelbine*/Vinorelbine*/adverse effects ; Vinorelbine*/Vinorelbine*/Vinorelbine*/administration & dosage ; Adverse Drug Reaction Reporting Systems*/Adverse Drug Reaction Reporting Systems*/Adverse Drug Reaction Reporting Systems*/statistics & numerical data

• Source: Expert opinion on drug safety [Expert Opin Drug Saf] 2024 Nov; Vol. 23 (11), pp. 1427-1437. Date of Electronic Publisher: Taylor & Francis Country of Publication: England NLM ID: 101163027 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Drug-associated congenital anomalies of the external ear identified in the United States food and drug administration adverse event reporting system database.

• Authors : Li X; Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.; Hao J

Subjects: Adverse Drug Reaction Reporting Systems* ; United States Food and Drug Administration* ; Databases, Factual*

• Source: Scientific reports [Sci Rep] 2024 Oct 09; Vol. 14 (1), pp. 23624. Date of Electronic Publication: 2024 Oct 09.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Sales Revenues for New Therapeutic Agents Approved by the United States Food and Drug Administration From 1995 to 2014.

• Authors : Wouters OJ; Department of Health Policy, London School of Economics and Political Science, London, England, UK. Electronic address: .; Kesselheim AS

Subjects: United States Food and Drug Administration* ; Drug Approval* ; Commerce*/Commerce*/Commerce*/economics

• Source: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2024 Oct; Vol. 27 (10), pp. 1373-1381. Date of Electronic Publisher: Elsevier Country of Publication: United States NLM ID: 100883818 Publication Model:

Record details

Cardiovascular events of Bruton's tyrosine kinase inhibitors: A real-world study based on the United States Food and Drug Administration Adverse Event Reporting System database.

• Authors : Zhao ZX; Department of Clinical Pharmacology, Sir Run Run Hospital, Nanjing Medical University, Nanjing, China.; Department of Clinical Pharmacy, School of Basic Medical Sciences and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.

Subjects: Adverse Drug Reaction Reporting Systems*/Adverse Drug Reaction Reporting Systems*/Adverse Drug Reaction Reporting Systems*/statistics & numerical data ; United States Food and Drug Administration* ; Piperidines*/Piperidines*/Piperidines*/adverse effects

• Source: British journal of clinical pharmacology [Br J Clin Pharmacol] 2024 Sep; Vol. 90 (9), pp. 2166-2179. Date of Electronic Publication: 2024 Jun 03.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

A post-marketing pharmacovigilance study of avapritinib: Adverse event data mining and analysis based on the United States Food and Drug Administration Adverse Event Reporting System database.

• Authors : Rong L; Department of Pharmacy, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.; School of Pharmacy, Bengbu Medical College, Bengbu, China.

Subjects: Adverse Drug Reaction Reporting Systems*/Adverse Drug Reaction Reporting Systems*/Adverse Drug Reaction Reporting Systems*/statistics & numerical data ; United States Food and Drug Administration* ; Data Mining*

• Source: British journal of clinical pharmacology [Br J Clin Pharmacol] 2024 Aug; Vol. 90 (8), pp. 1816-1826. Date of Electronic Publication: 2023 Feb 06.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

WHO and United States Food and Drug Administration extend the CRP-Lite pilot.

Subjects: United States Food and Drug Administration* ; World Health Organization*; Humans

• Source: Saudi medical journal [Saudi Med J] 2024 Jul; Vol. 45 (7), pp. 753.Publisher: Medical Services Department, Saudi Arabian Armed Forces, Ministry Of Defence And Aviation Country of Publication: Saudi Arabia NLM ID: 7909441

Record details

Antiviral influenza treatments and hemorrhage-related adverse events in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database.

• Authors : Sarker J; Department of Pharmacy Systems, Outcomes and Policy, College of Pharmacy, University of Illinois Chicago, Chicago, Illinois, USA.; Carkovic E

Subjects: Antiviral Agents*/Antiviral Agents*/Antiviral Agents*/adverse effects ; Adverse Drug Reaction Reporting Systems* ; United States Food and Drug Administration*

• Source: Pharmacotherapy [Pharmacotherapy] 2024 May; Vol. 44 (5), pp. 383-393. Date of Electronic Publication: 2024 Apr 24.Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 8111305 Publication Model:

Record details

Representation of women in clinical trials supporting FDA-approval of contemporary cancer therapies.

• Authors : Kalathoor S; Cardio-Oncology Program, Division of Cardiology, The Ohio State University Medical Center, Columbus, Ohio, USA.; Ghazi S

Subjects: Neoplasms*/Neoplasms*/Neoplasms*/drug therapy ; Neoplasms*/Neoplasms*/Neoplasms*/epidemiology ; Drug Approval*

• Source: International journal of cancer [Int J Cancer] 2024 Dec 01; Vol. 155 (11), pp. 1958-1968. Date of Electronic Publication: 2024 Aug 19.Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model:

Record details

Clinical Evidence Supporting FDA Approval of Gene and RNA Therapies for Rare Inherited Conditions.

• Authors : Odouard IC; Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, 624 N. Broadway, Hampton House 301, Baltimore, MD, 21205, USA.; Ballreich J

Subjects: United States Food and Drug Administration* ; Drug Approval* ; Rare Diseases*/Rare Diseases*/Rare Diseases*/drug therapy

• Source: Paediatric drugs [Paediatr Drugs] 2024 Nov; Vol. 26 (6), pp. 741-752. Date of Electronic Publication: 2024 Aug 05.Publisher: Springer International Country of Publication: Switzerland NLM ID: 100883685 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Reasons for Revision Surgery After Cervical Disk Arthroplasty Based on Medical Device Reports Maintained by the US Food and Drug Administration.

• Authors : Altorfer FCS; Department of Spine Surgery, Hospital for Special Surgery, New York, NY.; Kelly MJ

Subjects: Cervical Vertebrae*/Cervical Vertebrae*/Cervical Vertebrae*/surgery ; Reoperation*/Reoperation*/Reoperation*/statistics & numerical data ; United States Food and Drug Administration*

• Source: Spine [Spine (Phila Pa 1976)] 2024 Oct 15; Vol. 49 (20), pp. 1417-1425. Date of Electronic Publication: 2024 Jun 03.Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 7610646

Record details